Table 1.
Reviewed publications, by study type and outcome (n = 45)
First Author | Year Published | Study Type | Surveillance Type | Incidence outcome measure | Study country | Study Duration (Years) |
---|---|---|---|---|---|---|
Dedman [15] | 1998 | Surveillance | Passive | Norovirus disease | UK | 5 |
Wheeler [47] | 1999 | Cohort | Active | All gastroenteritis; Norovirus disease | UK | 3 |
Lopman [16] | 2003 | Surveillance | Passive | – | UK | 7 |
Froggatt [17] | 2004 | Surveillance | Passive | – | UK | 0.5 |
Sinclair [48] | 2005 | Cohort | Active | – | Australia | 1.5 |
Medici [42] | 2006 | Cohort | Passive | – | Italy | 1 |
Vernacchio [38] | 2006 | Cohort | Active | All gastroenteritis | USA | 1.5 |
Bucardo [43] | 2008 | Cohort | Passive | – | Nicaragua | 1 |
Gomara [39] | 2008 | Cohort | Active | – | UK | 1.25 |
Huhulescu [49] | 2009 | Cohort | Active | All gastroenteritis | Austria | 1 |
Iturriza-Gomara [40] | 2009 | Cohort | Active | All gastroenteritis | UK | 1.66 |
Gauci [52] | 2010 | Cross-sectional survey | Active | All gastroenteritis | Malta | 1.66 |
Kirk [27] | 2010 | Outbreak surveillance | Passive | – | Australia | 6 |
Kirk [50] | 2010 | Cohort | Active | – | Australia | 1 |
Liu [33] | 2010 | Surveillance | Passive | – | China | 1 |
Moyo [57] | 2011 | Cross-sectional survey | Passive | – | Tanzania | 0.25 |
Scallan [19] | 2011 | Surveillance | Passive | – | USA | 8 |
Vega [22] | 2011 | Outbreak surveillance | Passive | – | USA | 1 |
Baumann-Popczyk [53] | 2012 | Cross-sectional survey | Active | All gastroenteritis | Poland | 1 |
Oldak [35] | 2012 | Surveillance | Passive | All gastroenteritis | Poland | 1 |
Ouyang [34] | 2012 | Surveillance | Passive | – | China | 1 |
Tam [11] | 2012 | Cohort | Active | All gastroenteritis; Norovirus disease | UK | 1.33 |
Thouillot [24] | 2012 | Outbreak surveillance | Passive | – | France | 0.33 |
Ahmed [54] | 2013 | Cross-sectional survey | Active | All gastroenteritis | Dominica | 1.5 |
Gould [23] | 2013 | Outbreak surveillance | Passive | – | USA | 10 |
Ingram [55] | 2013 | Cross-sectional survey | Active | All gastroenteritis | Barbados | 1 |
Nahar [32] | 2013 | Surveillance | Passive | – | Bangladesh | 1 |
Payne [31] | 2013 | Surveillance | Active | Norovirus hospitalisation | USA | 2 |
Saupe [21] | 2013 | Surveillance | Passive | – | USA | 1.25 |
Trainor [36] | 2013 | Surveillance | Passive | – | Malawi | 10 |
Verhoef [56] | 2013 | Cross-sectional survey | Passive | Norovirus disease | Netherlands | 1 |
Arena [20] | 2014 | Surveillance | Passive | All gastroenteritis | France | 2 |
Barret [25] | 2014 | Outbreak surveillance | Passive | – | France | 1.5 |
Bernard [18] | 2014 | Surveillance | Passive | Norovirus disease | Germany | 8 |
Anders [45] | 2015 | Cohort | Active | All gastroenteritis | Vietnam | 4 |
Ballard [51] | 2015 | Cohort | Active | All gastroenteritis; Norovirus disease | Peru | 9 |
Enserink [41] | 2015 | Cohort | Active | All gastroenteritis | Netherlands | 3 |
Fernandez [37] | 2015 | Case–control | Passive | – | Colombia | not stated |
Gaspard [26] | 2015 | Outbreak surveillance | Active | – | France | 6 |
Lekana-Douki [44] | 2015 | Cohort | Passive | – | Gabon | 1.25 |
Leshem [30] | 2015 | Surveillance | Active | Norovirus hospitalisation | Isreal | 7 |
Platts-Mills [46] | 2015 | Cohort | Active | – | multi-site | 3 |
Sakon [28] | 2015 | Surveillance | Passive | – | Japan | 10 |
Thongprachum [29] | 2015 | Surveillance | Passive | – | Japan | 4 |
Xue [58] | 2015 | Cross-sectional survey | Active | – | China | 2 |